{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T20:32:01Z","timestamp":1786998721100,"version":"build-2736575974"},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","funder":[{"name":"the Ministry of Science and Technology of the People\u00e2\u20ac\u2122s Republic of China","award":["2022YFA1105002"],"award-info":[{"award-number":["2022YFA1105002"]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:sec>\n                    <jats:title>Background.<\/jats:title>\n                    <jats:p>Despite being promising candidates for treating acute graft-versus-host disease (aGvHD), the efficacy and underlying mechanisms of mesenchymal stem cells (MSCs) may vary based on their sources.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods.<\/jats:title>\n                    <jats:p>\n                      T-MSCs, derived from trophoblast cells, and BM-MSCs, derived from bone marrow cells, were investigated for their efficacy in alleviating aGvHD in humanized NOD.Cg-Prkdc\n                      <jats:sup>scid<\/jats:sup>\n                      Il2rg\n                      <jats:sup>tm1vst<\/jats:sup>\n                      \/Vst (NPG) mice. Clinical scoring and pathological damage were evaluated. Flow cytometry and cytometric bead array were used to assess T-cell proliferation and related cytokine release. Mechanisms involved in MSC-related efficacy were probed using different inhibitors and blocking antibodies.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results.<\/jats:title>\n                    <jats:p>\n                      An acute, single dose of T-MSCs (3\u2009\u00d7\u200910\n                      <jats:sup>5<\/jats:sup>\n                      cells\/mouse) or BM-MSCs (3\u2009\u00d7\u200910\n                      <jats:sup>5<\/jats:sup>\n                      cells\/mouse) significantly ameliorated aGvHD severity, whereas delayed, multiple doses of either MSC type did not. At the cellular level, both T-MSCs and BM-MSCs inhibited the proliferation of CD4\n                      <jats:sup>+<\/jats:sup>\n                      and CD8\n                      <jats:sup>+<\/jats:sup>\n                      \u2005T cells and the upregulation of related cytokines, possibly involving prostaglandin E\n                      <jats:sub>2<\/jats:sub>\n                      but not indoleamine 2,3-dioxygenase 1, transforming growth factor-\u03b2, or the programmed death-ligand 1 or Fas signaling. Additionally, the CD3\n                      <jats:sup>+<\/jats:sup>\n                      CD25\n                      <jats:sup>high<\/jats:sup>\n                      +Foxp3\n                      <jats:sup>+<\/jats:sup>\n                      \u2005T cells were increased by both MSC types.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions.<\/jats:title>\n                    <jats:p>\n                      Both T-MSCs and BM-MSCs can prevent CD4\n                      <jats:sup>+<\/jats:sup>\n                      and CD8\n                      <jats:sup>+<\/jats:sup>\n                      \u2005T-cell proliferation, possibly by facilitating prostaglandin E\n                      <jats:sub>2<\/jats:sub>\n                      release and promoting the proliferation of CD3\n                      <jats:sup>+<\/jats:sup>\n                      CD25\n                      <jats:sup>high<\/jats:sup>\n                      +Foxp3\n                      <jats:sup>+<\/jats:sup>\n                      \u2005T cells, thereby alleviating the development of aGvHD. T-MSCs and BM-MSCs may serve as promising candidates for treating aGvHD in the clinical setting.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/tp.0000000000005781","type":"journal-article","created":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T04:01:41Z","timestamp":1780977701000},"page":"e1649-e1656","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["A Comparative Study of Human Embryonic Stem Cell-derived Mesenchymal Stem Cells Through a Trophoblast-like Stage and Bone Marrow-derived Mesenchymal Stem Cells in Treating Acute Xenogeneic Graft-versus-Host Disease in Humanized Mice"],"prefix":"10.1097","volume":"110","author":[{"given":"Zhiyong","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Pharmacology, Shanghai Taichu Biotechnology Corporation Ltd, Shanghai, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaoyu","family":"Cheng","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Shanghai Taichu Biotechnology Corporation Ltd, Shanghai, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Shanghai Taichu Biotechnology Corporation Ltd, Shanghai, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Shanghai Taichu Biotechnology Corporation Ltd, Shanghai, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinfeng","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Shanghai Taichu Biotechnology Corporation Ltd, Shanghai, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyu","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Shanghai Taichu Biotechnology Corporation Ltd, Shanghai, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lianshan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Shanghai Taichu Biotechnology Corporation Ltd, Shanghai, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusheng Jason","family":"He","sequence":"additional","affiliation":[{"name":"Zhuhai Hengqin ImStem Biotechnology Co Ltd, Zhuhai, Guangdong, China."},{"name":"ImStem Biotechnology Inc, Farmington, CT."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren-He","family":"Xu","sequence":"additional","affiliation":[{"name":"Center of Reproduction, Development and Aging, and Institute of Translational Medicine, Faculty of Health Sciences, University of Macau, Taipa, Macau, China."},{"name":"Ministry of Education Frontiers Science Center for Precision Oncology, University of Macau, Taipa, Macau, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Shanghai Taichu Biotechnology Corporation Ltd, Shanghai, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,6,9]]},"reference":[{"key":"R1-20260817","doi-asserted-by":"crossref","first-page":"4373","DOI":"10.1158\/0008-5472.CAN-21-0301","article-title":"60 years young: the evolving role of allogeneic hematopoietic stem cell transplantation in cancer immunotherapy.","volume":"81","author":"Cieri","year":"2021","journal-title":"Cancer Res"},{"key":"R2-20260817","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-0-387-78580-6_1","article-title":"Principles and overview of allogeneic hematopoietic stem cell transplantation.","volume":"144","author":"Giralt","year":"2009","journal-title":"Cancer Treat Res"},{"key":"R3-20260817","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/1750-1172-2-35","article-title":"Acute graft versus host disease.","volume":"2","author":"Jacobsohn","year":"2007","journal-title":"Orphanet J Rare Dis"},{"key":"R4-20260817","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s41572-023-00438-1","article-title":"Acute graft-versus-host disease.","volume":"9","author":"Malard","year":"2023","journal-title":"Nat Rev Dis Primers"},{"key":"R5-20260817","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.3324\/haematol.2020.265769","article-title":"Improved outcome of patients with graft-versus-host disease after allogeneic hematopoietic cell transplantation for hematologic malignancies over time: an EBMT mega-file study.","volume":"107","author":"Greinix","year":"2022","journal-title":"Haematologica"},{"key":"R6-20260817","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.3390\/cells13181524","article-title":"Current approaches for the prevention and treatment of acute and chronic GVHD.","volume":"13","author":"Olivieri","year":"2024","journal-title":"Cells"},{"key":"R7-20260817","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1053\/bbmt.2002.v8.pm12171485","article-title":"Response of 443 patients to steroids as primary therapy for acute graft-versus-host disease: comparison of grading systems.","volume":"8","author":"MacMillan","year":"2002","journal-title":"Biol Blood Marrow Transplant"},{"key":"R8-20260817","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1097\/MOH.0b013e32834b6196","article-title":"Have we improved in preventing and treating acute graft-versus-host disease?","volume":"18","author":"Perez","year":"2011","journal-title":"Curr Opin Hematol"},{"key":"R9-20260817","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1177\/2040620713489842","article-title":"Treatment and management of graft-versus-host disease: improving response and survival.","volume":"4","author":"Garnett","year":"2013","journal-title":"Ther Adv Hematol"},{"key":"R10-20260817","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.bbmt.2011.09.003","article-title":"Mesenchymal stromal cells: a new tool against graft-versus-host disease?","volume":"18","author":"Baron","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"R11-20260817","doi-asserted-by":"crossref","first-page":"1241068","DOI":"10.3389\/fimmu.2023.1241068","article-title":"Novel therapies for graft versus host disease with a focus on cell therapies.","volume":"14","author":"Zeiser","year":"2023","journal-title":"Front Immunol"},{"key":"R12-20260817","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1002\/stem.2242","article-title":"Immune modulatory mesenchymal stem cells derived from human embryonic stem cells through a trophoblast-like stage.","volume":"34","author":"Wang","year":"2016","journal-title":"Stem Cells"},{"key":"R13-20260817","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/s41571-022-00721-2","article-title":"Humanized mouse models for immuno-oncology research.","volume":"20","author":"Chuprin","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"R14-20260817","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1634\/stemcells.2005-0008","article-title":"Role for interferon-gamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells.","volume":"24","author":"Krampera","year":"2006","journal-title":"Stem Cells"},{"key":"R15-20260817","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1038\/ni.3002","article-title":"Plasticity of mesenchymal stem cells in immunomodulation: pathological and therapeutic implications.","volume":"15","author":"Wang","year":"2014","journal-title":"Nat Immunol"},{"key":"R16-20260817","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1038\/s41375-018-0151-8","article-title":"Small hypoxia-primed mesenchymal stem cells attenuate graft-versus-host disease.","volume":"32","author":"Kim","year":"2018","journal-title":"Leukemia"},{"key":"R17-20260817","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1186\/s13287-023-03481-7","article-title":"Expansion of human bone marrow-derived mesenchymal stromal cells with enhanced immunomodulatory properties.","volume":"14","author":"Neo","year":"2023","journal-title":"Stem Cell Res Ther"},{"key":"R18-20260817","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1038\/s41598-021-81916-y","article-title":"Human amnion-derived mesenchymal stem cells attenuate xenogeneic graft-versus-host disease by preventing T cell activation and proliferation.","volume":"11","author":"Tago","year":"2021","journal-title":"Sci Rep"},{"key":"R19-20260817","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.lfs.2018.10.061","article-title":"Human placenta-derived mesenchymal stem cells ameliorate GVHD by modulating Th17\/Tr1 balance via expression of PD-L2.","volume":"214","author":"Ma","year":"2018","journal-title":"Life Sci"},{"key":"R20-20260817","doi-asserted-by":"crossref","first-page":"7761","DOI":"10.4049\/jimmunol.176.12.7761","article-title":"Bone marrow mesenchymal stem cells suppress lymphocyte proliferation in vitro but fail to prevent graft-versus-host disease in mice.","volume":"176","author":"Sudres","year":"2006","journal-title":"J Immunol"},{"key":"R21-20260817","doi-asserted-by":"crossref","first-page":"697854","DOI":"10.3389\/fimmu.2021.697854","article-title":"Regulatory T cells in GVHD therapy.","volume":"12","author":"Guo","year":"2021","journal-title":"Front Immunol"},{"key":"R22-20260817","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1182\/blood.2022019396","article-title":"New mechanisms of GVHD suppression by Tregs.","volume":"141","author":"Lederer","year":"2023","journal-title":"Blood"},{"key":"R23-20260817","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1182\/blood.2022017982","article-title":"Analysis of the T-cell repertoire and transcriptome identifies mechanisms of regulatory T-cell suppression of GVHD.","volume":"141","author":"Lohmeyer","year":"2023","journal-title":"Blood"},{"key":"R24-20260817","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1097\/TP.0b013e3181a5cb07","article-title":"Highly sensitive model for xenogenic GVHD using severe immunodeficient NOG mice.","volume":"87","author":"Ito","year":"2009","journal-title":"Transplantation"},{"key":"R25-20260817","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.clim.2014.11.004","article-title":"IL-10 exacerbates xenogeneic GVHD by inducing massive human T cell expansion.","volume":"156","author":"Abraham","year":"2015","journal-title":"Clin Immunol"},{"key":"R26-20260817","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1097\/00007890-199811150-00018","article-title":"Interleukin-10 dose-dependent regulation of CD4+ and CD8+ T cell-mediated graft-versus-host disease.","volume":"66","author":"Blazar","year":"1998","journal-title":"Transplantation"},{"key":"R27-20260817","doi-asserted-by":"crossref","first-page":"115102","DOI":"10.1016\/j.celrep.2024.115102","article-title":"Cell therapy with human IL-10-producing ILC2s limits xenogeneic graft-versus-host disease by inhibiting pathogenic T cell responses.","volume":"44","author":"Reid","year":"2025","journal-title":"Cell Rep"}],"container-title":["Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/TP.0000000000005781","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T20:00:24Z","timestamp":1786996824000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/TP.0000000000005781"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,9]]},"references-count":27,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/tp.0000000000005781","relation":{},"ISSN":["0041-1337","1534-6080"],"issn-type":[{"value":"0041-1337","type":"print"},{"value":"1534-6080","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,9]]}}}